No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ANTX AN2 Therapeutics
- 2.710
- +0.580+27.23%
Close Jul 3 13:00 ET
- 2.690
- -0.020-0.74%
Post 16:54 ET
80.84MMarket Cap-1079P/E (TTM)
2.720High2.200Low870.13KVolume2.200Open2.130Pre Close2.21MTurnover7.66%Turnover RatioLossP/E (Static)29.83MShares22.22052wk High0.73P/B30.78MFloat Cap1.91052wk Low--Dividend TTM11.36MShs Float23.580Historical High--Div YieldTTM24.41%Amplitude1.910Historical Low2.543Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Leerink Partners Upgrades AN2 Therapeutics to Outperform
Leerink Partners analyst Joseph Schwartz upgrades AN2 Therapeutics (NASDAQ:ANTX) from Market Perform to Outperform.
Express News | Octagon Capital Advisors LP Reports 10.1% Passive Stake in AN2 Therapeutics as of June 13 - SEC Filing
Leerink Partners Upgrades AN2 Therapeutics(ANTX.US) to Buy Rating, Maintains Target Price $5
Leerink Partners analyst Joseph Schwartz upgrades $AN2 Therapeutics(ANTX.US)$ to a buy rating, and maintains the target price at $5.According to TipRanks data, the analyst has a success rate of 41.5%
Optimistic Outlook for AN2 Therapeutics' Epetraborole Despite Initial Concerns
Express News | AN2 Therapeutics Inc : Leerink Partners Raises to Outperform From Market Perform
12 Health Care Stocks Moving In Friday's After-Market Session
GainersKineta (NASDAQ:KA) shares moved upwards by 28.5% to $0.67 during Friday's after-market session. The company's market cap stands at $8.1 million. iSpecimen (NASDAQ:ISPC) stock moved upwards by 1
Comments
$AN2 Therapeutics(ANTX.US$ Plan to report Phase 2 topline results in August 2024 from ongoing Phase 2/3 trial (EBO-301) in treatment-refractory Mycobacterium avium Complex (TR-MAC)
Phase 3 continues for 97 patients enrolled before the voluntary enrollment pause; lifting of the Phase 3 enrollment pause to be determined after review of unblinded Phase 2 data and discussions with the FDA
Phase 3 continues for 97 patients enrolled before the voluntary enrollment pause; lifting of the Phase 3 enrollment pause to be determined after review of unblinded Phase 2 data and discussions with the FDA
4
$AN2 Therapeutics(ANTX.US$ Do ur guys think the company already released the P2 results to their main investors?
2
$AN2 Therapeutics(ANTX.US$ is something brewing here
$AN2 Therapeutics(ANTX.US$ give us $ 5
1
$AN2 Therapeutics(ANTX.US$ So lets start here! Im basing my in on the bottom. And Y’all know i really likes me some bottoms! Hehehe! This just touched 52wk /ATL. And the daily is beyond into oversold! RSI 7= 7.91 and RSI 14=13.79! For those maybe not familiar? RSI 30 is considered OS territory. MACD has started to show signs of trying to go above giving us a golden cross. Will it? Possible. And one of my favorite indicators DPO. It also has started to ...
7
11
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
NVDAvsTSLA : No one knows the results only the company themselves
TrytosaveabitOP NVDAvsTSLA: That’s why I said ( upcoming ) meaning later when they release the results/data! If it’s good it could be a catalyst. Hehehe
NVDAvsTSLA TrytosaveabitOP: Agree. Back to $20 is easy once the tests are good
TrytosaveabitOP NVDAvsTSLA: That would be a great thing to see! GL to ya